Reset filter
Mots-clés
Afficher plus Mots-clés
Table des matières
  1. 1. Essai clinique
  2. 2. Routinedokumentation
  3. 3. Études de registres/cohortes
  4. 4. Assurance qualité
  5. 5. Standard de données
  6. 6. Questionnaire pour les patients
  7. 7. Spécialité médicale
    1. 7.1. Anesthésie
    1. 7.2. Dermatologie
    1. 7.3. HNO
    1. 7.4. Gériatrie
    1. 7.5. Gynécologie/obstétrique
    1. 7.6. Médecine interne
      1. Hématologie
      1. Infectiologie
      1. Cardiologie/angiologie
      1. Pneumologie
      1. Gastroentérologie
      1. Néphrologie
      1. Endocrinologie/métabolisme
      1. Rhumatologie
    1. 7.7. Neurologie
    1. 7.8. Ophtalmologie
    1. 7.9. Médecine palliative
    1. 7.10. Pathologie/médécine légale
    1. 7.11. Pédiatrie
    1. 7.12. Psychiatrie/psychosomatique
    1. 7.13. Radiologie
    1. 7.14. Chirurgie
      1. Chirurgie générale/viscérale
      1. Neurochirurgie
      1. Chirurgie plastique
      1. Chirurgie cardiaque/thoracique
      1. Chirurgie traumatologique/orthopédie
      1. Chirurgie vasculaire
    1. 7.15. Urologie
    1. 7.16. Médecine dentaire/MKG
Modèles de données sélectionnés

Vous devez être connecté pour sélectionner plusieurs modèles de données, les télécharger ou les analyser.

713 Résultats de recherche.
Pertinence Commentaire Plus récent Moins récent

MARS - Muenster Aging and Retina study Age-related macular degeneration - B. Eye diseases

- 20/09/2021 - 17 Formulaires, 1 Groupe Item, 83 Eléments de données, 1 Langue
Groupe Item: Eye disease
Age-related macular degeneration (AMD) is a retinal degenerative disease that occurs at an advanced age and is the major cause of central visual acuity loss and old-age blindness in its final stages. The aim of the MARS study is to identify factors that influence the progression and course of age-related macular degeneration in a prospective study. To date, the following studies have been carried out on the MARS cohort: MARS-I: 2001-2003; MARS-II: 2004 - 2007; MARS-III: 2007-2009; MARS +: 2010/11. The study is provided by Prof. Dr. Hense, Institute of Epidemiology and Social medicine, University Clinic of Muenster.

Administrative documentation

1 Groupe Item 16 Eléments de données

A. Self-assessment of visual acuity

1 Groupe Item 9 Eléments de données

Interview

1 Groupe Item 5 Eléments de données

D. Slit lamp biomicroscopy I

1 Groupe Item 18 Eléments de données

H.Quality of Life

1 Groupe Item 24 Eléments de données

I. Family History

1 Groupe Item 21 Eléments de données

Acrylate Intraocular Lenses in Cataract Surgery of Uveitis Patients - Eligibility

- 03/06/2017 - 1 Formulaire, 2 Groupes Item, 6 Eléments de données, 1 Langue
Groupes Item: Inclusion Criteria, Exclusion Criteria
ODM derived from http://clinicaltrials.gov/ct2/show/record/NCT00403832

Swedish National Quality Registry for Cataracts (NCR Nationella Kataraktregistret) - Formulär 2B: 2018 års kataraktregistrering - Uppföljningsformulär (Follow-up Form for registering of cataracs in 2018, Part B)

- 09/07/2018 - 2 Formulaires, 6 Groupes Item, 23 Eléments de données, 2 Langues
Groupes Item: Follow-up status, Final control, Visual Acuity right eye, Visual Acuity left eye, Conditions of operated eye, Responsible Physician for final follow-up
Swedish National Quality Registry for Cataracts (NCR Nationella Kataraktregistret) Head of Registry: Anders Behndig, Professor, Norrland University Hospital, Umeå, Sweden. Adress of Registry: Nationella Kataraktregistret Landstinget Blekinge 371 81 KARLSKRONA Sweden Source: http://rcsyd.se/kataraktreg/registrering/formular-nationella-kataraktregistret This ODM-File is derived from "Formulär 2A/B: 2018 års kataraktregistrering - Uppföljningsformulär" (Follow-up Form for registering of cataracs in 2018). Part A to be filled after surgery, Part B to be filled when medical checks after the current cataract surgery are not longer needed and glasses can be prescribed, but not later than 3 months after surgery. In practice, the end date is between 6 weeks and 3 months after surgery depending on type of cataract surgery and postoperative course. Attention: All varibales are mandatory. English translation not validated.

Formulär 2A: 2018 års kataraktregistrering - Uppföljningsformulär (Follow-up Form for registering of cataracs in 2018, Part A)

8 Groupes Item 17 Eléments de données

LASER ADMINISTRATION FELLOW EYE (UNSCHEDULED) CRFs Roche FVF4170G Macular Edema NCT00473382

- 28/06/2017 - 1 Formulaire, 2 Groupes Item, 10 Eléments de données, 1 Langue
Groupes Item: Patient administration, LASER ADMINISTRATION STUDY EYE
Terms of use: You may not use this document or the information contained herein to a regulatory authority in connection with an application for a marketing authorization or any other regulatory submission without the express written consent of Roche Study #: FVF4168g Drug: Ranibizumab Study Title: A Phase III, Double-Masked, Multicenter, Randomized, Sham-Controlled Study Of The Efficacy And Safety Of Ranibizumab Injection In Subjects With Clinically Significant Macular Edema With Center Involvement Secondary To Diabetes Mellitus

ICHOM Cataracts - Post-operative Clinical Form - Outcomes

- 30/04/2020 - 1 Formulaire, 3 Groupes Item, 16 Eléments de données, 1 Langue
Groupes Item: Administrative Data, Post-operative visual status, Post-operative complications
CATARACTS DATA COLLECTION Version 2.0.1 Revised: March 8th, 2017, International Consortium for Health Outcomes Measurement (ICHOM), Source: http://www.ichom.org/ Notice: This work was conducted using resources from ICHOM, the International Consortium for Health Outcomes Measurement (www.ICHOM.org). The content is solely the responsibility of the authors and does not necessarily represent the official views of ICHOM. Conditions: Symptomatic Cataract | Asymptomatic Cataract Treatment Approaches: Phacoemulsification | Sutured Extracapsular Cataract Extraction | Sutureless Extracapsular Cataract Extraction | Intracapsular Cataract Extraction Scores: Catquest-9SF - The Catquest-9SF is free for all health care organizations, and a license is not needed for use. By Mats Lundström et al. This ODM-file contains the post-operative clinical form. The items are to be filled in with clinical or administrative data, collected within three months after cataract surgery. Publication: Mahmud I, Kelley T, Stowell C, et al. A Proposed Minimum Standard Set of Outcome Measures for Cataract Surgery. JAMA Ophthalmol. 2015;133(11):1247–1252. doi:10.1001/jamaophthalmol.2015.2810 For this version of the standard set, semantic annotation with UMLS CUIs has been added.

ICHOM Cataracts - Patient-Reported Visual Function (pre- and post-operative)

- 30/04/2020 - 1 Formulaire, 2 Groupes Item, 11 Eléments de données, 1 Langue
Groupes Item: Administrative Data, Patient-reported visual function
CATARACTS DATA COLLECTION Version 2.0.1 Revised: March 8th, 2017, International Consortium for Health Outcomes Measurement (ICHOM), Source: http://www.ichom.org/ Notice: This work was conducted using resources from ICHOM, the International Consortium for Health Outcomes Measurement (www.ICHOM.org). The content is solely the responsibility of the authors and does not necessarily represent the official views of ICHOM. Conditions: Symptomatic Cataract | Asymptomatic Cataract Treatment Approaches: Phacoemulsification | Sutured Extracapsular Cataract Extraction | Sutureless Extracapsular Cataract Extraction | Intracapsular Cataract Extraction Scores: Catquest-9SF - The Catquest-9SF is free for all health care organizations, and a license is not needed for use. By Mats Lundström This ODM-file contains pre- and post-operative patient froms. To be filled in by patient prior to and within 3 months after surgery. Publication: Mahmud I, Kelley T, Stowell C, et al. A Proposed Minimum Standard Set of Outcome Measures for Cataract Surgery. JAMA Ophthalmol. 2015;133(11):1247–1252. doi:10.1001/jamaophthalmol.2015.2810 For this version of the standard set, semantic annotation with UMLS CUIs has been added.

ICHOM Cataracts - Pre- and intraoperative Clinical Form

- 20/09/2021 - 1 Formulaire, 8 Groupes Item, 33 Eléments de données, 1 Langue
Groupes Item: Administrative Data, Demographic factors, Baseline visual status, Ocular Comorbidities, Prior ophthalmic interventions, Technical Factors, Treatment Variables, Intra-operative Complications
CATARACTS DATA COLLECTION Version 2.0.1 Revised: March 8th, 2017 International Consortium for Health Outcomes Measurement (ICHOM), Source: http://www.ichom.org/ Notice: This work was conducted using resources from ICHOM, the International Consortium for Health Outcomes Measurement (www.ICHOM.org). The content is solely the responsibility of the authors and does not necessarily represent the official views of ICHOM. Conditions: Symptomatic Cataract | Asymptomatic Cataract Treatment Approaches: Phacoemulsification | Sutured Extracapsular Cataract Extraction | Sutureless Extracapsular Cataract Extraction | Intracapsular Cataract Extraction Scores: Catquest-9SF - The Catquest-9SF is free for all health care organizations, and a license is not needed for use. by Mats Lundström et al. This ODM-file contains the pre-operative and intra-operative clinical Form. The items are to be filled in with clinical or administrative data, collected pre- or intraoperatively. Publication: Mahmud I, Kelley T, Stowell C, et al. A Proposed Minimum Standard Set of Outcome Measures for Cataract Surgery. JAMA Ophthalmol. 2015;133(11):1247–1252. doi:10.1001/jamaophthalmol.2015.2810 For this version of the standard set, semantic annotation with UMLS CUIs has been added.

Study Eye Selection Screening Ranibizumab Macular Edema Secondary To Branch Retinal Vein Occlusion FVF4165g - Study Eye Selection Screening

- 18/03/2018 - 1 Formulaire, 1 Groupe Item, 7 Eléments de données, 1 Langue
Groupe Item: study eye
Study part: Study Eye Selection Screening. A Phase III, Multicenter, Randomized, Sham Injection-Controlled Study Of The Efficacy And Safety Of Ranibizumab Injection Compared With Sham In Subjects with Macular Edema Secondary To Branch Retinal Vein Occlusion.

Study Eye Selection Screening Ranibizumab Macular Edema Diabetes Mellitus FVF4168g - Study Eye Selection Screening

- 20/03/2018 - 1 Formulaire, 1 Groupe Item, 6 Eléments de données, 1 Langue
Groupe Item: study eye
Study part: Study Eye Selection Screening. A Phase III, Double-Masked, Multicenter, Randomized, Sham-Controlled Study Of The Efficacy And Safety Of Ranibizumab Injection In Subjects With Clinically Significant Macular Edema With Center Involvement Secondary To Diabetes Mellitus.

Study Eye Selection Screening Ranibizumab Macular Edema Diabetes Mellitus FVF4170g - Study Eye Selection Screening

- 21/03/2018 - 1 Formulaire, 1 Groupe Item, 6 Eléments de données, 1 Langue
Groupe Item: study eye
Study part: Study Eye Selection Screening. A Phase III, Double-Masked, Multicenter, Randomized, Sham-Controlled Study Of The Efficacy And Safety Of Ranibizumab Injection In Subjects With Clinically Significant Macular Edema With Center Involvement Secondary To Diabetes Mellitus.

STUDY EYE SELECTION (SCREENING) CRFs Roche FVF4168G Macular Edema NCT00473330

- 08/06/2017 - 1 Formulaire, 2 Groupes Item, 6 Eléments de données, 1 Langue
Groupes Item: Patient administration, Eligibility Criteria
Terms of use: You may not use this document or the information contained herein to a regulatory authority in connection with an application for a marketing authorization or any other regulatory submission without the express written consent of Roche Study #: FVF4168g Drug: Ranibizumab Study Title: A Phase III, Double-Masked, Multicenter, Randomized, Sham-Controlled Study Of The Efficacy And Safety Of Ranibizumab Injection In Subjects With Clinically Significant Macular Edema With Center Involvement Secondary To Diabetes Mellitus

Vision Testing (Eye) Pazopanib Macular Degeneration MD1103367 - Vision Testing (Eye)

- 10/06/2018 - 1 Formulaire, 6 Groupes Item, 22 Eléments de données, 1 Langue
Groupes Item: Subjective Refraction Right Eye, Subjective Refraction Left Eye, Visual Acuity, lntraocular Pressure, Slip Lamp Examination, Fundus Examination
Study part: Vision Testing (Eye). A phase 1 single-masked, randomized (with respect to placebo), placebo-controlled, parallel-group, dose-rising study to evaluate the safety, tolerability and pharmacokinetics of repeat oral doses of GW786034 in elderly healthy volunteers. Trade Name: Votrient. Clinical Study ID: MD1103367.

Aide

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial